Clinical Trials Browser

Triple Negative Breast Neoplasms × olaparib × 90 days × Clear all

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01116648 2026-05-28

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05933265 2026-05-04

Study of LP-184 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms